These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16054932)

  • 21. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
    Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
    Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations?
    Heart Advis; 2005 Feb; 8(2):3. PubMed ID: 15806687
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacotherapy for obesity--promise and uncertainty.
    Yanovski SZ
    N Engl J Med; 2005 Nov; 353(20):2187-9. PubMed ID: 16291989
    [No Abstract]   [Full Text] [Related]  

  • 24. Rimonabant in obese patients with type 2 diabetes.
    Shapiro H; Singer P
    Lancet; 2007 Feb; 369(9561):553-4; author reply 554-5. PubMed ID: 17307091
    [No Abstract]   [Full Text] [Related]  

  • 25. Novel therapies for cardiometabolic risk reduction and implications for clinical practice.
    Watson KE
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S37-42. PubMed ID: 17934393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Less weight or more hype with rimonabant?
    Drug Ther Bull; 2007 Jun; 45(6):41-3. PubMed ID: 17583228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans.
    Bergholm R; Sevastianova K; Santos A; Kotronen A; Urjansson M; Hakkarainen A; Lundbom J; Tiikkainen M; Rissanen A; Lundbom N; Yki-Järvinen H
    Int J Obes (Lond); 2013 May; 37(5):699-703. PubMed ID: 22828945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endocannabinoid receptor antagonists and other emerging pharma-cological strategies for weight reduction.
    Gadde KM
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):549-56. PubMed ID: 16503875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors.
    Pagotto U; Pasquali R
    Lancet; 2005 Apr 16-22; 365(9468):1363-4. PubMed ID: 15836868
    [No Abstract]   [Full Text] [Related]  

  • 30. Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
    Wierzbicki AS
    Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Nutrition-obesity. Rimonabant and cardiovascular risk factors].
    Vincent M; Golay A
    Rev Med Suisse; 2009 Jan; 5(185):49-52. PubMed ID: 19216325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
    Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C
    Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy.
    Aronne LJ; Isoldi KK
    Am J Cardiol; 2007 Dec; 100(12A):18P-26P. PubMed ID: 18154742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions.
    Sander GE; Giles TD
    Am J Geriatr Cardiol; 2006; 15(4):255-9. PubMed ID: 16849895
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.
    Ruilope LM; Després JP; Scheen A; Pi-Sunyer X; Mancia G; Zanchetti A; Van Gaal L
    J Hypertens; 2008 Feb; 26(2):357-67. PubMed ID: 18192851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The endocannabinoid system and treatment of obesity].
    Aronsen L
    Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cardiac metabolic risk factors. CB1-blocker corrects three with one stroke].
    MMW Fortschr Med; 2006 Aug; 148(35-36):48. PubMed ID: 16995368
    [No Abstract]   [Full Text] [Related]  

  • 38. What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management?
    Jensen MD
    Am J Med; 2007 Sep; 120(9 Suppl 1):S25-31; discussion S31-2. PubMed ID: 17720358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Rimonabant helps in overweight patients with multiple cardiovascular risk factors such as type 2 diabetes].
    Golay A
    Rev Med Suisse; 2008 Aug; 4(168):1828. PubMed ID: 18814768
    [No Abstract]   [Full Text] [Related]  

  • 40. The endocannabinoid system as a novel approach for managing obesity.
    Lillo JL
    J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.